Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Beier, Rita  [Clear All Filters]
2023
Wintering A, Tischer-Zimmermann S, Schultze-Florey R, Beier R, Sauer M, Blasczyk R, Heim A, Eiz-Vesper B, Maecker-Kolhoff B. Adenoviral penton and hexon proteins are equivalent immunogenic targets of virus-specific T cells after HSCT in children. Transplant Cell Ther. 2023.
Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft H-G, Arseniev L, Beier R, Beutel G, Cario G, et al. Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors. J Clin Invest. 2023.
Li X, Kalwak K, Beier R, Kehne J, Möller A-K, Baumgart J, Beelen DW, Hilger RA, Vora A, Sykora K-W. Population pharmacokinetic modeling of treosulfan and rationale for dose recommendation in children treated for conditioning prior to allogeneic hematopoietic stem cell transplantation. Drug Metab Pharmacokinet. 2023;52:100515.
Erlacher M, Andresen F, Sukova M, Stary J, de Moerloose B, Bosch Jvan der We, Dworzak M, Seidel MG, Polychronopoulou S, Beier R, et al. Spontaneous remission and loss of monosomy 7: a window of opportunity for young children with SAMD9L syndrome. Haematologica. 2023.
Böhm S, Wustrau K, Schmid JPachlopnik, Prader S, Ahlman M, Yacobovich J, Beier R, Speckmann C, Behnisch W, Ifversen M, et al. Survival in primary hemophagocytic lymphohistiocytosis 2016-2021: etoposide is better than its reputation. Blood. 2023.
Sykora K-W, Beier R, Schulz A, Cesaro S, Greil J, Goździk J, Sedlacek P, Bader P, Schulte J, Zecca M, et al. Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial. Bone Marrow Transplant. 2023.